SEC Comment Letter 0000000000-25-001353 to Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc.
Date: Feb. 7, 2025 · CIK: 0001755237 · Accession: 0000000000-25-001353
AI Filing Summary & Sentiment
File numbers found in text: 333-284690
Letter
February 7, 2025 Regina Graul, Ph.D. President and Chief Executive Officer Cyclerion Therapeutics, Inc. 245 First Street, 18th Floor Cambridge, Massachusetts, 02142 Re:Cyclerion Therapeutics, Inc. Registration Statement on Form S-3 Filed February 4, 2025 File No. 333-284690 Dear Regina Graul Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:William J. Michener
Show Raw Text
February 7, 2025
Regina Graul, Ph.D.
President and Chief Executive Officer
Cyclerion Therapeutics, Inc.
245 First Street, 18th Floor
Cambridge, Massachusetts, 02142
Re:Cyclerion Therapeutics, Inc.
Registration Statement on Form S-3
Filed February 4, 2025
File No. 333-284690
Dear Regina Graul Ph.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:William J. Michener